会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Anticancer agents
    • 抗癌剂
    • US06683083B1
    • 2004-01-27
    • US10089718
    • 2002-08-02
    • Noboru KanekoKazuto Nishio
    • Noboru KanekoKazuto Nishio
    • A61K31496
    • A61K31/496
    • Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formula [1]: wherein R represents: or a pharmaceutically acceptable salt thereof. Compared with conventional anticancer agents, these agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesions.
    • 本文公开了抑制需要这种治疗的哺乳动物中癌细胞生长的方法,包括向所述哺乳动物施用抑制量的由以下通式[1]表示的二苯基甲基哌嗪:其中R表示:或药学上 与常规抗癌剂相比,这些药物毒性较小,对各种固体癌症具有优异的制癌作用。 此外,这些抗癌剂抑制成纤维细胞的增殖,这使得它们对肺纤维化和增生性瘢痕疙瘩病变有效。
    • 8. 发明申请
    • Method of Diagnosing Pancreatic Cancer with the Use of N-Binding Type Sugar Chains
    • 使用N-结合型糖链诊断胰腺癌的方法
    • US20110065141A1
    • 2011-03-17
    • US12991340
    • 2009-05-08
    • Tokuzo AraoKazuko MatsumotoKazuto NishioHiroki SakamotoMasayuki KitanoMasatoshi Kudo
    • Tokuzo AraoKazuko MatsumotoKazuto NishioHiroki SakamotoMasayuki KitanoMasatoshi Kudo
    • C12Q1/37C12Q1/34
    • G01N33/57438Y10T436/24
    • The present invention is to provide a novel marker for diagnosing pancreatic cancer, a method for determining if a subject has pancreatic cancer utilizing the marker, etc. The present inventors collected blood from patients of 78 cases in total including patients of 24 cases with pancreaticobiliary-duct benign disorder (16 gallstone cases and 8 pancreatitis cases) and patients of 54 cases with pancreatic cancer, and mass spectrometry was performed on N-linked sugar chains in plasma. From the 74 mass-spectrometric peaks detected, 65 sugar chains were extracted based on the results of PAM analysis. These extracted sugar chains were then used to predict pancreatic cancer or pancreaticobiliary-duct benign disorder, to correctly diagnose 74% cases. Further, a T-test was performed between the two groups, the group of pancreaticobiliary-duct benign disorder and the group of pancreatic cancer, which identified two sugar chains, the sugar chain of m/z 3031 and the sugar chain of m/z 2362, as sugar chains demonstrating significant difference (p
    • 本发明提供一种用于诊断胰腺癌的新型标记物,用于确定受试者是否使用标记物的胰腺癌的方法等。本发明人从78例患者中收集了总共包括24例胰腺胆管癌患者的血液, 膀胱良性疾病(16例胆囊病例和8例胰腺炎病例)和54例胰腺癌患者,并对血浆中的N链糖链进行质谱分析。 根据PAM分析结果,从检测到的74个质谱峰中提取出65个糖链。 然后将这些提取的糖链用于预测胰腺癌或胰胆管良性疾病,以正确诊断74%的病例。 此外,在两组之间进行T检验,即胰胆管良性病变组和胰腺癌组,鉴定了两条糖链,m / z 3031的糖链和m / z的糖链 2362,由于糖链显示出显着性差异(p <0.05),并且两组之间的表达水平呈现2倍或更大的差异。 使用这些糖链的正确检测率用六个分类器计算,所有这些分类器都得到约70%的正确检测结果。